Fact-checked by Grok 2 weeks ago

Prostate-specific antigen

Prostate-specific antigen (PSA), also known as kallikrein-related peptidase 3 (KLK3), is a glycoprotein enzyme and serine protease produced primarily by the columnar epithelial cells of the prostate gland in males.^[1]^[2] Encoded by the KLK3 gene located on the long arm of chromosome 19 at position 19q13.33-13.41, PSA belongs to the kallikrein family of proteases and plays a key physiological role in seminal fluid by cleaving high-molecular-weight proteins such as semenogelin I and II, thereby facilitating semen liquefaction post-ejaculation to promote sperm motility.^[2]^[3]^[4] In clinical contexts, circulating PSA levels in serum serve as a biomarker for prostate pathology, with elevations observed in conditions including prostate cancer, benign prostatic hyperplasia, and prostatitis, prompting its introduction as a diagnostic aid in the late 1980s.^[1]^[5] The test's implementation revolutionized early detection of prostate cancer, yet its routine use for population screening remains contentious due to suboptimal specificity and sensitivity, resulting in frequent false positives that drive unnecessary biopsies and the detection of slow-growing tumors prone to overtreatment without clear survival gains for many patients.^[6]^[7] Large-scale randomized trials, such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), have demonstrated a modest 20% relative reduction in prostate cancer mortality with PSA screening, though at the cost of substantial overdiagnosis rates exceeding 50% in some cohorts.^[8]^[9] This tension underscores ongoing efforts to refine PSA-based strategies with adjunctive markers or risk stratification to maximize benefits while minimizing harms.^[6]

Biochemistry and Structure

Molecular Composition and Gene Expression

Prostate-specific antigen (PSA) is encoded by the KLK3 gene, located at chromosomal position 19q13.33 within a cluster of kallikrein-related peptidase genes.^[2]^[10] The gene produces a preproenzyme transcript that, after signal peptide cleavage and activation, yields the mature PSA protein.^[10] The mature PSA molecule is a single-chain serine protease glycoprotein with a molecular mass of approximately 33 kDa and 237 amino acid residues.^[10] Its primary structure includes a catalytic triad typical of kallikrein peptidases, consisting of histidine, aspartic acid, and serine residues (His57, Asp102, Ser195 in chymotrypsin-like numbering), enabling proteolytic activity.^[11] Post-translational modifications, notably N-linked glycosylation at asparagine 69, account for about 8% of PSA's mass and influence its stability and secretion.^[12] KLK3 expression is predominantly confined to the epithelial cells of the prostate gland, where transcript levels are markedly elevated (RPKM 4286.7).^[2] Androgen regulation drives this tissue-specific expression, with the androgen receptor binding to promoter and enhancer elements, including those derived from long terminal repeats, to activate transcription in response to hormonal signals.^[13]

Enzymatic Properties

Prostate-specific antigen (PSA), encoded by the KLK3 gene and also known as kallikrein-related peptidase 3, is a chymotrypsin-like serine protease characterized by a catalytic triad typical of this family.^[14] Its enzymatic activity involves nucleophilic attack by the serine residue on peptide bonds, enabling hydrolysis primarily after large hydrophobic amino acids such as tyrosine and leucine at the P1 position, with a distinctive capability to cleave after glutamine—a feature uncommon among serine proteases.^[15] This specificity arises from the S1 substrate-binding pocket, which features a polar base with Ser189, Ser226, and Thr190, contrasting with the more hydrophobic pocket in canonical chymotrypsin and restricting access to smaller substrates.^[15] PSA's primary proteolytic targets are the high-molecular-weight semenogelin proteins I and II, abundant in seminal fluid, where it cleaves multiple sites—approximately 40% involving glutamine—to degrade the seminal clot and promote liquefaction post-ejaculation.^[15] Kinetic studies demonstrate relatively low catalytic efficiency compared to chymotrypsin, with Km values around 1.6–5.7 mM and kcat of 0.19–0.75 s⁻¹ for synthetic substrates, reflecting four orders of magnitude reduced activity; nonetheless, it achieves 50% degradation of semenogelin I in 11 minutes under physiological conditions.^[14] Activity is assayed effectively at pH 7.7, aligning with near-neutral to slightly alkaline optima suitable for seminal plasma.^[14] The enzyme is synthesized as an inactive zymogen, proPSA, featuring an N-terminal pro-peptide that maintains latency until proteolytic removal, often facilitated by other kallikreins like KLK2, exposes the active site.^[16] Once activated, PSA's protease function is modulated by inhibitors; in seminal fluid, zinc ions bind tightly as a competitive inhibitor, while in serum, it forms irreversible complexes with alpha-1-antichymotrypsin, neutralizing activity and stabilizing the protein.^[14]^[17] Crystal structures, including those from the 2000s such as PDB 2ZCK, confirm these regulatory elements and the extended substrate recognition grooves beyond the S1 site, underscoring PSA's adaptation for high-molecular-weight protein substrates.^[15]

Physiological Roles and Production

Sources in Normal Physiology

Prostate-specific antigen (PSA), a serine protease enzyme, is produced exclusively by the columnar epithelial cells of the prostate gland's glandular acini and ducts in normal physiology.^[16] Immunohistochemical analyses demonstrate that PSA expression is highly specific to these prostatic epithelial cells, with negligible immunoreactivity observed in other normal tissues, confirming its primary localization to the prostate under non-pathological conditions.^[18] While trace PSA expression has been detected via immunohistochemistry in extraprostatic sites such as urethral glands, salivary ducts, and periurethral tissues, these levels are minimal and do not contribute significantly to systemic circulation.^[19]^[5] Under normal conditions, PSA is secreted primarily into the seminal plasma, comprising a major component of prostatic fluid that liquefies semen post-ejaculation, with concentrations ranging from 0.5 to 5 mg/mL.^[20] A small fraction diffuses into the bloodstream across the prostate's basement membrane and vascular endothelium, yielding serum concentrations typically below 4 ng/mL in healthy adult males.^[1] These serum levels exhibit age-dependent elevation, attributed to gradual prostate glandular enlargement, with median values rising from approximately 0.7 ng/mL in men aged 40–49 years to 1.5–2.0 ng/mL in those over 70 years.^[21]^[1]

Regulation and Secretion Mechanisms

The expression of prostate-specific antigen (PSA), encoded by the KLK3 gene, is primarily regulated at the transcriptional level by androgens through the androgen receptor (AR) pathway. Dihydrotestosterone (DHT), the principal ligand in prostatic tissue due to its higher affinity for AR compared to testosterone, binds to AR in the cytoplasm, promoting its dimerization, nuclear translocation, and binding to androgen response elements (AREs) in the KLK3 promoter and enhancer regions.^[13] This AR-mediated activation induces KLK3 transcription, with studies in prostate cell lines demonstrating up to 100-fold increases in PSA mRNA following DHT exposure.^[22] Additional cofactors, such as enhancer RNAs from the KLK3 locus, facilitate chromatin looping to enhance AR recruitment and gene activation.^[23] Following transcription and translation in prostatic epithelial cells, PSA is synthesized as an inactive zymogen precursor (pro-PSA), consisting of 244 amino acids with an N-terminal propeptide of 7 residues. The protein undergoes post-translational modifications, including N-linked glycosylation at two sites (Asn45 and Asn69), during transit through the endoplasmic reticulum (ER) and Golgi apparatus.^[24] Mature PSA is then packaged into secretory granules and released via exocytosis into the prostatic ductal lumina, contributing to seminal plasma where concentrations reach 0.1–5 mg/mL.^[4] This apical secretion resembles an apocrine process, with holocrine elements in hyperplastic or neoplastic tissue potentially increasing passive leakage into circulation.^[16] Secretion rates exhibit temporal variations influenced by androgen rhythms; longitudinal studies report circadian fluctuations in serum PSA mirroring testosterone peaks, with mean ranges of 0.37 ng/mL (28% variation) from nadir to zenith, typically higher in early morning.^[25] Age-related increases in PSA production and secretion occur progressively, with median serum levels rising from 0.7 ng/mL in men in their 40s to 2.1 ng/mL in their 70s over 16-year follow-ups, attributable to prostatic epithelial hyperplasia and sustained AR signaling.^[26] In seminal fluid, PSA activity is modulated post-secretion by inhibitors like protein C inhibitor (PCI), which forms complexes to limit proteolysis of substrates such as semenogelins, indirectly constraining feedback on prostatic output through microenvironmental regulation.^[27]

Measurement and Variants

Serum Levels and Influencing Factors

Serum prostate-specific antigen (PSA) levels in asymptomatic men without prostate cancer generally range from 0 to 2.5 ng/mL for ages 40-49, 0 to 3.5 ng/mL for ages 50-59, 0 to 4.5 ng/mL for ages 60-69, and 0 to 6.5 ng/mL for ages 70 and older, with these age-adjusted upper limits accounting for gradual prostate enlargement over time.^[28]^[29] These reference ranges derive from population-based cohorts excluding men with known prostate pathology. To address inter-assay discrepancies observed in early commercial tests, the World Health Organization established an international reference standard in the late 1990s, comprising 90% PSA complexed with alpha-1-antichymotrypsin and 10% free PSA, enabling calibration for improved measurement comparability across laboratories.^[30]^[31] Non-pathologic factors significantly modulate serum PSA concentrations. Larger prostate volume, as seen in benign prostatic hyperplasia, positively correlates with PSA levels (r ≈ 0.6 in transrectal ultrasound studies), attributable to increased glandular tissue producing more PSA per unit volume.^[32] Ejaculation induces a transient elevation, with mean increases of 0.8-1.0 ng/mL peaking 1 hour post-ejaculation and resolving within 24-48 hours in men aged 49-79, due to mechanical disruption of prostate epithelial barriers.^[33]^[34] Pharmacologic agents like 5α-reductase inhibitors (e.g., finasteride or dutasteride) suppress PSA by approximately 50% after 6-12 months of use, reflecting reduced prostate epithelial cell volume and androgen-dependent PSA gene expression.^[35]^[36] Ethnic disparities in baseline PSA are documented, with men of African ancestry showing 10-20% higher median levels (e.g., 0.2-0.5 ng/mL greater than European ancestry men) in cancer-free cohorts, independent of age or prostate volume, based on large-scale screening data.^[37]^[38] Intra-individual fluctuations contribute additional variability, with coefficients of variation up to 20-30% in serial measurements from annual screening programs, influenced by assay imprecision, physiologic rhythms, and unmeasured confounders, underscoring the value of confirmatory testing.^[39]^[40]

PSA Isoforms and Derivatives

Prostate-specific antigen (PSA) circulates in serum predominantly as free PSA (fPSA), which constitutes 10-30% of total PSA and remains unbound to plasma proteins, and complexed PSA (cPSA), comprising 70-90% and primarily forming covalent bonds with alpha-1-antichymotrypsin (ACT). A minor fraction of cPSA binds to alpha-2-macroglobulin (A2M), creating large encapsulated complexes that evade detection by most immunoassays due to steric hindrance.^[41]^[42] Free PSA exhibits a monomeric structure of approximately 33 kDa, while ACT-complexed forms reach 90-100 kDa, influencing their separation in analytical techniques like gel electrophoresis.^[43] Within fPSA, distinct isoforms include intact mature PSA, precursor proPSA variants such as [-2]proPSA, and internally cleaved or nicked forms like benign PSA (BPSA). ProPSA isoforms arise from incomplete processing of the 7-amino-acid proleader peptide on the preproPSA precursor, resulting in truncated structures (e.g., [-2]proPSA retains a dipeptide prosegment after clipping at the -2 position) that lack enzymatic activity and resist activation by proteases such as human kallikrein 2 (hK2) or trypsin. Nicked variants, characterized by internal peptide bond cleavages (e.g., at Lys145-Lys146 in BPSA), similarly display reduced chymotrypsin-like serine protease function due to structural disruption of the active site. These isoforms occur in comparable concentrations within the free fraction under normal conditions.^[44]^[45]^[46] Immunoassays for isoform detection employ monoclonal antibodies selective for conformational epitopes unique to free versus complexed forms or specific truncations, enabling differentiation without enzymatic assays. For instance, antibodies targeting the propeptide sequence distinguish [-2]proPSA from mature fPSA. Free PSA isoforms prove more labile during sample storage than cPSA, with measurable degradation (e.g., 0.9% monthly loss at -20°C) attributed to protease susceptibility and conformational instability, whereas complexed forms remain stable across temperatures from 4°C to -70°C for up to 9 months.^[47]^[48]

Dynamics and Velocity

Prostate-specific antigen (PSA) velocity refers to the rate of change in serum PSA concentration over time, typically expressed as nanograms per milliliter per year (ng/mL/year), calculated from serial measurements at least 12 to 18 months apart to minimize assay variability and short-term fluctuations.^[49] This metric captures longitudinal trends in PSA levels, with thresholds such as greater than 0.35 ng/mL/year or 0.4 ng/mL/year associated with increased risk of detecting aggressive prostate pathology, independent of absolute PSA values.^[50]^[51] Higher velocities, such as exceeding 0.75 ng/mL/year in men with PSA levels between 4 and 10 ng/mL, have been linked to prognostic concerns for rapid progression kinetics.^[52] PSA doubling time (PSADT), a related kinetic parameter, quantifies the exponential growth phase by estimating the duration required for PSA levels to double, often derived from the formula PSADT = (ln(2) × time interval) / ln(PSA2 / PSA1), where PSA1 and PSA2 are sequential measurements.^[53] Shorter PSADTs, such as less than 48 months in example cohorts, indicate more aggressive underlying processes, while longer times suggest indolent changes; calculations assume exponential rise and require log-transformation of PSA values to stabilize variance and normalize skewed distributions.^[54]^[55] Short-term PSA dynamics include acute elevations, such as post-biopsy spikes that can increase levels up to 10-fold within hours and persist for up to four weeks due to tissue trauma, necessitating a delay of at least six weeks before repeat testing to avoid misinterpretation.^[56] Long-term serial assessments, as in large screening cohorts like the European Randomized Study of Screening for Prostate Cancer (ERSPC), reveal gradual upward trends influenced by age and prostate volume, with intra-individual variability often exceeding 20-50% year-to-year even without pathology.^[57] A 2025 analysis of annual testing in over 100,000 men without diagnosed prostate cancer demonstrated significant intra-individual fluctuations, where 54% of those with PSA ≥2.5 ng/mL normalized below this threshold on retest, highlighting the limitations of single measurements for prognostic inference.^[39]^[58] Mathematical models of PSA kinetics frequently employ logarithmic transformations to account for proportional variability and heteroscedasticity, enabling robust estimation of velocity and PSADT in heterogeneous populations; for instance, log2(PSA) adjustments in regression analyses reduce skewness and improve predictive accuracy for trend extrapolation.^[55]^[59] These approaches underscore that velocity and doubling time provide additive prognostic value beyond static levels, reflecting underlying proliferative rates, though thresholds remain debated due to assay imprecision and biological noise.^[54]

Clinical Diagnostic Applications

Screening for Prostate Cancer

Prostate-specific antigen (PSA) testing serves as the primary tool for early detection of prostate cancer in asymptomatic men, typically involving serial measurement of serum PSA levels to identify elevations prompting further evaluation such as biopsy.^[60] Major guidelines endorse PSA-based screening through shared decision-making, weighing individual risks and preferences against potential benefits. The American Urological Association (AUA) and Society of Urologic Oncology (SUO) 2023 guidelines recommend initiating discussion of PSA screening for average-risk men aged 55-69 years, with baseline PSA measurement followed by repeat testing every 2-4 years if initial levels are low (<3 ng/mL).^[60] Digital rectal examination (DRE) may accompany PSA but is not mandatory as a standalone screening method.^[61] Randomized controlled trials provide empirical support for PSA screening's impact on mortality. The European Randomized Study of Screening for Prostate Cancer (ERSPC), involving over 162,000 men screened every 4 years with PSA cutoffs of 3.0 ng/mL, reported a 21% relative reduction in prostate cancer-specific mortality after 13 years of follow-up, sustained in longer-term analyses up to 16 years.^[62] This equates to an absolute risk reduction of approximately 1.28 deaths per 1,000 men screened, though lead-time bias—where screening advances detection without altering disease course—must be considered in interpreting trial durations.60525-0/abstract) Detection rates for clinically significant cancers (Gleason score ≥7) reach sensitivities of about 80% at PSA thresholds of 3-4 ng/mL, enabling identification of aggressive tumors amenable to curative intervention.^[5] Risk-adapted strategies tailor screening intervals and starting ages to elevate detection in high-risk populations. For men with family history of prostate cancer, Black ancestry, or germline mutations (e.g., BRCA2), guidelines advocate earlier initiation, such as from age 40-45, with more frequent testing.^[63] The European Society for Medical Oncology (ESMO) updated recommendations in 2025 specify annual PSA screening starting at age 40 for carriers of BRCA1 or BRCA2 mutations, reflecting heightened prostate cancer incidence and aggressiveness in these groups.^[64] Baseline PSA in younger high-risk men also informs personalized velocity tracking for subsequent monitoring.^[60]

Diagnosis, Staging, and Monitoring

In the diagnostic confirmation of prostate cancer following biopsy, serum PSA levels provide prognostic information regarding tumor aggressiveness. Elevated preoperative PSA concentrations, particularly exceeding 10 ng/mL, are associated with higher Gleason scores on biopsy pathology, indicating more aggressive disease, though the correlation strength varies across studies with reported Pearson coefficients around 0.59.^[65] ^[66] Higher PSA levels post-biopsy also predict greater likelihood of biochemical failure after radical prostatectomy compared to biopsy Gleason score alone.^[66] For staging, PSA integrates with clinical stage and biopsy Gleason score in nomograms such as the Partin tables to estimate pathological outcomes, including organ-confined disease, extracapsular extension, seminal vesicle invasion, and lymph node involvement. Updated Partin tables from cohorts treated between 2006 and 2011 incorporate PSA levels (median 4.9 ng/mL in validation sets) to predict these probabilities, aiding decisions on surgical or therapeutic approaches.^[67] ^[68] Post-treatment monitoring relies on PSA nadir and dynamics to assess response and detect recurrence. After radical prostatectomy, an undetectable PSA nadir below 0.2 ng/mL strongly predicts prolonged recurrence-free survival, while higher nadirs correlate with increased risk of biochemical progression.^[69] Biochemical recurrence is defined as two consecutive PSA values of 0.2 ng/mL or greater following prostatectomy, prompting evaluation for salvage therapies.^[70] ^[71] In advanced prostate cancer, PSA velocity—typically a rise exceeding 0.75 ng/mL per year—signals potential metastatic progression or treatment resistance, guiding imaging and therapy escalation.^[16] In metastatic hormone-sensitive disease, as evaluated in the CHAARTED trial, achieving a PSA nadir below 0.2 ng/mL by 6-7 months after initiating androgen deprivation therapy with docetaxel predicts superior overall survival, with updated 10-year data showing over 50% of such patients alive versus poorer outcomes in those failing this threshold.^[72] For castrate-resistant progression, rising PSA despite castrate testosterone levels (below 50 ng/dL) defines non-response, with velocities informing timing of next-line agents like enzalutamide.^[73]

Evaluation of Benign Conditions

Benign prostatic hyperplasia (BPH) frequently causes elevations in serum PSA levels that correlate with increasing prostate volume, as larger glands produce more PSA.^[5] Prostate-specific antigen density (PSAD), calculated as total PSA divided by prostate volume in cm³, aids in distinguishing BPH from malignancy; values below 0.15 ng/mL/cm³ are typically associated with benign conditions in men with PSA levels of 4-10 ng/mL.^[74] In cohort studies of BPH patients, mean PSAD has been reported as low as 0.084 ng/mL/cm³, contrasting with higher values in cancerous prostates.^[75] Acute prostatitis, particularly bacterial infections, can produce marked PSA spikes exceeding 20 ng/mL and occasionally surpassing 1,000 ng/mL due to inflammation-induced glandular disruption.^[76] These elevations often resolve following antibiotic therapy, with PSA levels declining to baseline within 1-2 months in responsive cases, allowing differentiation from persistent cancer-related rises.^[1] Chronic prostatitis may also elevate PSA, but normalization is achievable with combined antibiotics and anti-inflammatory treatment, underscoring the need for clinical correlation and repeat testing.^[77] Procedures such as transurethral resection of the prostate (TURP) for BPH result in substantial PSA reductions, typically 40-70% depending on resected tissue volume, as removal decreases PSA-producing glandular elements.^[78] Post-TURP PSA levels stabilize within 60 days, dropping to below 2 ng/mL in many benign cases, though incomplete normalization may occur if residual prostate tissue remains.^[79] Such changes provide diagnostic context for monitoring benign recovery but require awareness of procedural artifacts in interpreting subsequent elevations.^[80] Despite these patterns, PSA exhibits low specificity for prostate cancer detection in the "gray zone" of 4-10 ng/mL, where benign conditions account for 60-80% of elevations, yielding a positive predictive value for malignancy of approximately 20-25%.^[81] This limitation necessitates adjunctive tools like multiparametric MRI or biopsy for accurate differential diagnosis, as isolated PSA reliance risks unnecessary interventions from non-malignant causes.^[82]

Controversies and Evidence-Based Assessment

Benefits: Mortality Reduction and Detection Efficacy

Prostate cancer mortality rates in the United States declined by more than 50% from their peak in the early 1990s through 2023, a period aligning with the broad implementation of PSA screening, according to Surveillance, Epidemiology, and End Results (SEER) program data. This substantial reduction, from approximately 30 deaths per 100,000 men in 1993 to about 19 per 100,000 by 2019-2023, is linked to PSA-enabled early detection, which facilitated interventions before disease progression.^[83] ^[84] ^[85] The European Randomized Study of Screening for Prostate Cancer (ERSPC) provides randomized evidence of PSA screening's impact, showing a 20% relative reduction in prostate cancer-specific mortality after 9 years of follow-up, with benefits strengthening over time to yield larger absolute reductions at 16 years (rate ratio 0.79) and 21 years, including decreased metastasis rates.^[86] ^[87] ^[88] In subgroup analyses from ERSPC centers, relative risk reductions reached 37% in regions like Sweden and the Netherlands with extended follow-up.^[62] PSA screening has induced a stage shift toward earlier detection, increasing the proportion of localized cancers diagnosed from around 60% in the pre-PSA era to over 80% in contemporary cohorts, thereby enabling curative treatments and averting metastatic progression.^[89] ^[90] This shift correlates with lower incidences of advanced disease in screened populations.^[91] Among high-risk groups, such as African American men—who face 1.7-2.1 times higher prostate cancer mortality than white men—earlier PSA screening from age 40 yields amplified benefits, potentially reducing deaths by about 30% through targeted detection of aggressive tumors.^[92] ^[93] Similarly, younger men (ages 40-50) in high-risk categories, including those with family history, demonstrate enhanced mortality reductions with proactive screening, as affirmed by 2023-2024 guideline updates and modeling showing 9 fewer prostate cancer deaths per 1,000 screened over a lifetime.^[63] ^[94]

Risks: Overdiagnosis, False Positives, and Overtreatment

Overdiagnosis arises from PSA screening detecting prostate cancers that are indolent and unlikely to progress to clinical significance during a man's lifetime, as evidenced by autopsy studies revealing latent tumors in 20% to 50% of men over age 50 without prior symptoms.^[95] ^[96] In the European Randomized Study of Screening for Prostate Cancer (ERSPC), achieving one mortality benefit required screening 781 men aged 55 to 69, highlighting the imbalance between detected cases and lives saved, with 27 men needing diagnosis (and potential treatment) per prevented death.^[97] ^[98] False-positive results occur in 70% to 80% of cases at a 4 ng/mL PSA cutoff, where elevated levels prompt biopsies that confirm no cancer, exposing men to procedural risks including infection (up to 5% in some series), bleeding, and sepsis, alongside elevated healthcare costs and anxiety.^[99] ^[100] Over a decade of screening every 2 to 4 years, more than 15% of men experience at least one false-positive result, per U.S. Preventive Services Task Force analysis of trial data.^[97] Overtreatment follows when low-risk cancers—often Gleason score ≤6 and low volume—are subjected to aggressive interventions like radical prostatectomy, with 50% to 75% of such cases historically receiving definitive therapy despite indolent potential.^[101] These procedures yield urinary incontinence in 5% to 20% of patients at one year and erectile dysfunction in 30% to 50%, based on long-term cohort outcomes.^[102] ^[103] Active surveillance protocols demonstrate low progression, with grade group upgrades in only 24% at 5 years and 36% at 10 years for initial low-grade tumors, underscoring opportunities to avoid unnecessary harms.^[104]

Guideline Debates and Recent Empirical Data

The U.S. Preventive Services Task Force (USPSTF) shifted its stance on PSA screening from a 2012 grade D recommendation against routine use for all men to a 2018 grade C recommendation for ages 55-69, advising individualized decisions via clinician discussions on potential benefits and harms, while maintaining a grade D against screening for men 70 years and older.^[97] In contrast, the American Urological Association (AUA) guidelines endorse broader PSA-based screening, recommending baseline testing for average-risk men at ages 50-55 and earlier (40-45 years) for high-risk groups such as Black men or those with family history, with repeat evaluations to confirm elevations before biopsy referral.^[60] These divergences reflect ongoing debates over balancing mortality benefits against overdiagnosis risks, with AUA emphasizing empirical reductions in advanced disease detection through systematic protocols. Extended follow-up data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial, with median 17 years of observation through 2015, reported no statistically significant prostate cancer mortality reduction overall (rate ratio 1.09, 95% CI 0.87-1.36), largely attributed to high PSA testing contamination in the control arm, where over 40% received screening outside protocol.^[105] Subgroup analyses of adherent participants, however, indicated potential benefits, with re-evaluations suggesting 27-32% relative mortality reductions when accounting for compliance and contamination, challenging dismissals of screening efficacy.^[106] Conversely, the European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated a 20% relative reduction in prostate cancer deaths after 13 years (rate ratio 0.80, 95% CI 0.65-0.98), sustained in 16-year updates, providing causal evidence from lower-contamination settings that distinguishes true prevention from lead-time bias, where earlier detection advances diagnosis timelines without altering death dates.^[86] A September 2025 analysis of over 100,000 men undergoing annual PSA testing revealed substantial intra-individual variability, with 54% (95% CI 53-56%) of those exceeding 2.5 ng/mL reverting below this threshold on subsequent tests, and only 12% consistently elevated across multiple draws, underscoring the limitations of fixed cutoffs and supporting personalized thresholds informed by age, genetics, and serial trends to mitigate false positives.^[107] Such findings urge guideline refinements toward repeat confirmatory testing rather than immediate biopsy, addressing uncertainties in prior trials where single elevations drove overtreatment. Critiques of restrictive guidelines highlight overemphasis on overdiagnosis—estimated at 50% in models incorporating lead-time of 5-8 years—while undervaluing causal mortality impacts, as ERSPC's design minimizes bias and aligns with observational data showing 20-50% drops in metastatic cases post-screening adoption, countering narratives that prioritize harms without equivalent scrutiny of untreated progression risks.^[108] These debates prioritize randomized causal evidence over contamination-flawed null results, advocating organized screening protocols to maximize net benefits.

Non-Clinical Uses and Emerging Developments

Forensic Applications

Prostate-specific antigen (PSA), also referred to as P30 in forensic contexts, functions as a presumptive biomarker for semen identification in criminal investigations, given its production by prostatic epithelial cells and secretion into seminal plasma at concentrations of 0.2–5.5 mg/mL.^[109] This specificity arises from PSA's role in liquefying semen post-ejaculation, distinguishing it from other body fluids except trace prostatic secretions.^[110] Detection methods include classical immunodiffusion techniques, such as Ouchterlony double diffusion in agar, and quantitative enzyme-linked immunosorbent assays (ELISA), which achieve sensitivities down to nanogram levels in extracts from stains or swabs.^[111]^[112] Modern rapid lateral flow immunoassays, like the ABAcard p30 or Seratec PSA Semiquant, provide results in minutes via monoclonal antibody capture, enabling on-site or high-throughput laboratory screening of evidence such as clothing stains, vaginal, oral, or rectal swabs.^[113] These assays confirm semen presence even in azoospermic or vasectomized samples lacking spermatozoa. PSA testing demonstrates superior persistence compared to acid phosphatase assays, remaining detectable in vaginal swabs up to 48 hours or longer post-intercourse, versus acid phosphatase's rapid degradation.^[114] It offers higher specificity, avoiding false positives from non-prostatic phosphatases in vaginal or fecal matter, and enhanced stability in heat-, moisture-, or time-degraded exhibits, as validated in casework comparisons where PSA outperformed acid phosphatase in mixed or diluted samples.^[115]^[109] Limitations include false negatives from excessive dilution, such as post-washing of garments or swabs, which reduces PSA below detection thresholds of 1–4 ng/mL for many kits.^[116] The high-dose hook effect can also yield negatives in highly concentrated undiluted semen due to antibody saturation.^[117] Trace PSA in non-seminal sources, including male urine (up to microgram levels) or female genital secretions, risks interpretive errors without confirmatory microscopy or DNA analysis, though such instances are rare and typically below forensic cutoffs.^[118] Combined presumptive testing mitigates these issues, with PSA serving as the preferred confirmatory marker in U.S. forensic protocols.^[119]

Integration with Novel Biomarkers

The Prostate Health Index (PHI), calculated as the ratio of [-2]pro-proPSA to free and total PSA, enhances specificity for clinically significant prostate cancer detection in men with PSA levels in the 4-10 ng/mL gray zone compared to PSA alone, thereby reducing false positives and unnecessary biopsies.^[120] Recent studies, including those post-2020, affirm PHI's diagnostic superiority, with improved risk stratification when combined with multiparametric MRI, as evidenced by higher specificity for Gleason score ≥7 cancers.^[121] Although FDA-approved in 2012, ongoing meta-analyses validate its role in refining PSA-based decisions, particularly in initial biopsy settings.^[122] The 4Kscore test combines four kallikrein biomarkers—total PSA, free PSA, intact PSA, and human kallikrein 2—with clinical variables like age and prior biopsy history to estimate the probability of high-grade (Gleason ≥7) prostate cancer on biopsy. Clinical utility trials from 2023-2025 demonstrate it reduces biopsy rates by approximately two-thirds in routine practice while preserving detection of aggressive disease, with area under the curve values exceeding 0.80 for discrimination.^[123]^[124] Integration with PSA triage has shown consistent calibration across diverse cohorts, supporting its use to avoid overdiagnosis in low-risk elevations.^[123] Exosome-based assays, such as the ExoDx Prostate (IntelliScore), analyze urinary exosomal RNA from three genes (PCA3, ERG, SPDEF) to predict high-grade prostate cancer risk, offering complementary stratification to PSA in equivocal cases without requiring digital rectal exam. Validated studies indicate it performs robustly alongside PSA and mpMRI for layered decision-making, identifying men suitable for biopsy deferral with negative predictive values around 90% for Gleason Grade Group ≥2 disease.^[125]^[126] Shifts toward AI-enhanced multi-biomarker panels incorporate PSA with kallikreins, exosomes, and polygenic risk scores, yielding higher sensitivity and specificity than PSA monotherapy, as per 2024-2025 evaluations. In high-risk groups, such as BRCA1/2 mutation carriers—who face elevated odds of aggressive prostate cancer—2025 ESMO guidance endorses annual PSA screening starting at age 40, with integrated biomarkers facilitating targeted surveillance and reducing overtreatment through refined risk modeling.^[127]^[64]^[128]

Historical Development

Discovery and Early Characterization

In 1971, Japanese forensic scientist Mitsuwo Hara and colleagues isolated a glycoprotein from human seminal plasma, designating it γ-seminoprotein due to its antigenic specificity for semen detection in criminal investigations, such as rape cases.^[129] This protein exhibited unique physicochemical properties, including a molecular weight of approximately 33,000 Da and resistance to certain enzymatic degradations, distinguishing it from other seminal components.^[4] Subsequent analyses confirmed its prostate origin and high concentration in semen (up to 1-3 mg/mL), though its enzymatic function remained unclear at the time.^[130] In 1979, Ming C. Wang and coworkers at Roswell Park Memorial Institute purified a distinct prostate-specific antigen (initially termed prostate antigen) directly from human prostatic tissue extracts using chromatographic techniques, achieving homogeneity as evidenced by a single band on polyacrylamide gel electrophoresis.^[131] Immunological assays demonstrated its tissue exclusivity to the prostate, with no cross-reactivity in other organs, and preliminary enzymatic tests suggested proteolytic activity, later refined to identify it as a chymotrypsin-like serine protease by the mid-1980s.^[132] This purification marked a key biochemical milestone, enabling production of specific antisera for further characterization.^[133] Early radioimmunoassays for γ-seminoprotein (now PSA) in semen were established around 1980, leveraging polyclonal antibodies to achieve detection limits sufficient for forensic applications.^[134] Concurrently, molecular studies in the 1980s led to cloning of the encoding gene, KLK3, revealing a 261-amino-acid preproenzyme with a signal peptide and androgen-responsive promoter elements that regulate expression in vitro via androgen receptor binding.^[4] These findings solidified PSA's role as an androgen-dependent glandular kallikrein, primarily secreted into seminal fluid to facilitate liquefaction through substrate cleavage.

Adoption as a Clinical Biomarker

The transition of prostate-specific antigen (PSA) from a research tool to a clinical biomarker accelerated in the mid-1980s with the commercialization of sensitive immunoassays. In 1986, Hybritech Incorporated developed the Tandem-R PSA assay, the first monoclonal antibody-based test capable of reliably measuring PSA in serum at concentrations as low as 0.1 ng/mL, which received U.S. Food and Drug Administration (FDA) approval that year specifically for monitoring disease progression and treatment response in patients with known prostate cancer.^[30] Concurrently, Mayo Clinic Laboratories introduced a similar polyclonal assay, enabling broader laboratory access and facilitating initial clinical evaluations. These assays marked a shift from earlier less sensitive methods, such as radioimmunoassays, which had limited detection capabilities and higher variability.^[135] By the late 1980s, accumulating evidence from prospective studies demonstrated PSA's utility in detecting prostate cancer in asymptomatic men, despite its initial regulatory restriction to monitoring. For instance, research published in 1987 established that serum PSA levels above 10 ng/mL were strongly associated with prostate cancer presence, prompting off-label use for early detection.^[136] This informal adoption expanded rapidly in the early 1990s, driven by urologists' observations of improved localization of clinically significant tumors when combined with digital rectal examination. In August 1994, the FDA expanded approval to include PSA as an aid for prostate cancer screening in men over 50, when used alongside digital rectal examination, formalizing its role in routine clinical practice.^[137]^[138] Widespread implementation post-1994 correlated with a marked surge in prostate cancer diagnoses, reflecting enhanced detection of early-stage disease. U.S. incidence rates rose dramatically from approximately 106,000 cases annually in 1990 to over 184,000 by 1995, according to Surveillance, Epidemiology, and End Results (SEER) program data, attributable to increased PSA testing rather than true epidemiological shifts.^[85] To address inter-assay variability—initially ranging from 20% to 50% due to differences in antibody specificity and calibration—manufacturers aligned calibrators to the Hybritech standard, with subsequent international efforts, including World Health Organization reference preparations established in the late 1990s, further harmonizing measurements across platforms.^[139] This standardization supported more consistent clinical thresholds, typically 4 ng/mL for initiating further evaluation, though adoption varied by region due to cost and access barriers.^[30]

Key Studies and Regulatory Milestones

The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, involving 76,693 men randomized to annual PSA screening for six years or usual care, reported in 2009 no significant difference in prostate cancer mortality rates after 7 to 10 years of follow-up (1.60 deaths per 10,000 person-years in the screening group versus 1.65 in the control group).^[140] Extended analyses through 13 years confirmed the absence of a mortality benefit, with high rates of PSA testing (up to 52%) in the control arm contributing to potential dilution of effect.^[141] In parallel, the European Randomized Study of Screening for Prostate Cancer (ERSPC), encompassing over 162,000 men across multiple centers, yielded contrasting results: initial 2009 findings indicated a 20% relative reduction in prostate cancer deaths at 9 years, with subsequent 16-year follow-up in 2019 strengthening this to a number needed to invite of 570 to prevent one death.^[142] ^[87] A 2023 analysis at 21 years further refined benefits, showing sustained reductions in advanced disease progression and mortality alongside decreased metastasis rates, attributing efficacy to organized, less contaminated screening protocols.00172-4/fulltext) These trials prompted regulatory shifts: the U.S. Preventive Services Task Force (USPSTF) in 2012 issued a grade D recommendation against routine PSA-based screening for asymptomatic men aged 50 to 74, citing insufficient net benefit due to overdiagnosis risks outweighing mortality gains in population-level data.^[143] Countering this, the American Urological Association's 2023 guidelines positioned PSA testing as central to early detection, advocating shared decision-making with baseline screening offered from ages 45 to 50 for average-risk men and intervals of 2 to 4 years thereafter, informed by ERSPC's long-term evidence.^[63] Targeted milestones emerged for high-risk cohorts; in 2025, the European Society for Medical Oncology recommended annual PSA screening starting at age 40 for BRCA1 and BRCA2 mutation carriers, based on elevated lifetime prostate cancer risks (up to 30% for BRCA2) and evidence of earlier-onset aggressive disease, aiming to enable stage-appropriate intervention.^[64] This aligns with updated European Association of Urology guidelines endorsing enhanced surveillance in germline mutation carriers.^[144]

References

[1]
Prostate-Specific Antigen (PSA) Test - NCI - National Cancer Institute
Jan 31, 2025 · Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. Both prostate cancer and ...
[2]
KLK3 kallikrein related peptidase 3 [ (human)] - NCBI
Aug 19, 2025 · KLK3 single nucleotide polymorphisms were associated with serum prostate-specific antigen (PSA) levels in African-Americans but not in European- ...
[3]
Proteolytic Activity of Prostate-Specific Antigen (PSA) towards ...
The main biological function of PSA is the liquefaction of the clot formed after ejaculation by cleavage of semenogelins I and II in seminal fluid. PSA also ...
[4]
PROSTATE-SPECIFIC ANTIGEN: Its Discovery and Biochemical ...
Based on its function, amino-acid structure, and gene location in 19q13.2 to 19q13.4, PSA is recognized as a member of the human kallikrein family.
[5]
Prostate-Specific Antigen Testing - Medscape Reference
Jul 16, 2025 · Prostate-specific antigen (PSA) is a protein produced by normal as well as neoplastic prostate cells. This enzyme participates in the ...
[6]
Prostate cancer screening: Continued controversies and novel ... - NIH
Aug 31, 2022 · This literature review focuses on the limitations of PSA-specific PCa screening, reasons behind the screening controversy, and the novel biomarkers and ...Urine Biomarkers · Tissue Biomarkers · 6.2. Biomarkers As...
[7]
Prostate-specific antigen-based screening: controversy and guidelines
Mar 24, 2015 · Some feared that PSA screening would contribute to overdiagnosis and subsequent overtreatment of PCa, with potential net unfavorable effects on ...No Benefit With Psa... · Conclusions · Abbreviations
[8]
Controversies in prostate cancer screening - ScienceDirect.com
This study found that PSA-based screening reduced the rate of death from prostate cancer by 20%, but was associated with a high risk of overdiagnosis [24]. PSA- ...
[9]
Prostate-specific antigen for prostate cancer screening ... - PubMed
Screening for prostate cancer with the prostate-specific antigen (PSA) test remains controversial. This controversy is reflected in a lack of consensus in ...
[10]
Entry - *176820 - KALLIKREIN-RELATED PEPTIDASE 3; KLK3 - OMIM
Human prostate-specific antigen (APS) is a kallikrein-like protease present in seminal plasma. It is a single-chain glycoprotein with a molecular mass of ...
[11]
Characterization of the Prostate-Specific Antigen (PSA) Catalytic ...
Jul 28, 2014 · PSA shows a conserved position of the Asp102/His57/Ser195 catalytic triad [4] (see Fig. 1). ... In addition, PSA is the only member of the ...
[12]
Comprehensive Characterization of the Glycosylation Site of Human ...
... PSA is encoded by KLK3 gene. PSA has been commonly reported as a glycoprotein with a single glycosylation site at N69. An approximately 8% of PSA weight ...
[13]
Long Terminal Repeats Act as Androgen-Responsive Enhancers for ...
Here, we show that KLK3 is one of a specific cluster of androgen-regulated genes at the centromeric end of the kallikrein locus with enhancers that evolved from ...
[14]
Proteolytic Activity of Prostate-Specific Antigen (PSA) towards ...
Sep 19, 2014 · Prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3) exerts chymotrypsin-like proteolytic activity.
[15]
PROSTATE-SPECIFIC ANTIGEN IS A “CHYMOTRYPSIN-LIKE ... - NIH
PSA displays chymotrypsin-like specificity, cleaving after hydrophobic residues, in addition to possessing a unique ability to cleave after glutamine in the P1 ...
[16]
Prostate-Specific Antigen - StatPearls - NCBI Bookshelf - NIH
Sep 10, 2024 · PSA is a serine protease enzyme produced by the columnar epithelium of prostatic tissue. The proenzymatic intracellular form of PSA is pro-PSA.Missing: enzymatic | Show results with:enzymatic
[17]
Mutational Analysis of Prostate‐Specific Antigen Defines the Intrinsic ...
Jun 8, 2016 · PSA is secreted as a zymogen (proPSA) with an inhibitory prodomain that must be removed for full activity.
[18]
Prognostic and diagnostic role of PSA immunohistochemistry - NIH
Sep 10, 2019 · In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9–100% (1:800–1 ...
[19]
PSA - NordiQC - Immunohistochemical Quality Control
PSA is highly specific for prostate glandular epithelium. A few normal tissues at extraprostatic sites do, however, express PSA. These include scattered cells ...<|control11|><|separator|>
[20]
Prostate Specific Antigen - an overview | ScienceDirect Topics
PSA is found in seminal plasma in concentrations from 0.5 to 5 mg mL− 1 whereas, PSA in serum of men 50–80 years of age without prostate disease is 1000-fold ...
[21]
Reference Ranges of Age-Related Prostate-Specific Antigen in Men ...
In current study, the proportion of men with PSA level less than 4.0g/ml was 100% for 40-49 year-old age group, 98.7% for 50-59 year-old age group, and the ...
[22]
Suppression of androgen receptor-mediated gene expression by a ...
The regulation of prostate-specific antigen (PSA) (KLK3) expression by AR has been extensively studied as a model for AR-mediated gene activation (4–7).
[23]
Enhancer RNAs participate in androgen receptor-driven looping that ...
Apr 28, 2014 · Furthermore, our data show that KLK3 eRNA (KLK3e) selectively enhances the gene expression of AR-regulated genes, and provide evidence for a ...
[24]
Characterization of the Precursor of Prostate-specific Antigen
The precursor or zymogen form of prostate-specific antigen (pro-PSA) is composed of 244 amino acid residues including an amino-terminal propiece of 7 amino ...
[25]
Temporal (circadian) and functional relationship between prostate ...
The mean circadian range of change (ROC) from lowest to highest values for PSA was 0.37 ± 0.07 ng/mL (28 ± 9%), and for testosterone it was 202 ± 23 ng/dL (53 ± ...Missing: secretion | Show results with:secretion
[26]
Sixteen-Year Longitudinal Changes in Serum Prostate-Specific ...
Serum PSA levels at baseline increased with increasing decade of age. The median serum PSA levels were 0.7, 0.9, 1.4, and 2.1 ng/mL for men in their 40s ...
[27]
Specific Antigen and Protein C Inhibitor
These findings suggested that PCI bound to Sg in seminal vesicles regulates the PSA-catalyzed degradation of Sg in seminal plasma, and that the binding of PCI ...Missing: feedback | Show results with:feedback
[28]
Prostate-Specific Antigen (PSA) Test - Cleveland Clinic
PSA is a protein that your prostate gland makes. Normal and cancerous prostate tissue make PSA. But prostate cancer tends to produce PSA in higher amounts.Missing: expression | Show results with:expression<|separator|>
[29]
What Is a Normal PSA Level by Age? - David B Samadi, MD
Apr 18, 2025 · Age Group. Typical PSA Range (ng/mL) ; 40–49 years. 0.0 – 2.5 ; 50–59 years. 0.0 – 3.5 ; 60–69 years. 0.0 – 4.5 ; 70–79 years. 0.0 – 6.5 ...
[30]
Twenty Years of PSA: From Prostate Antigen to Tumor Marker - PMC
Calibration of PSA assays to the World Health Organization (WHO) standard ... The age-specific PSA reference range can be used to increase specificity for cancer.
[31]
Continued provision of WHO International Standards for total and ...
The need for standardization of PSA assays was recognised in the 1990s and prompted two conferences organised by Professor Thomas Stamey of Stanford University ...
[32]
Relationship of Prostate-Specific Antigen and Prostate Volume in ...
Studies in Japanese, South Korean, and Indian patients showed a positive significant correlation coefficient between PSA and PV of 0.65, 0.41, and 0.78, ...
[33]
Ejaculation increases the serum prostate-specific antigen ... - PubMed
Conclusions: Ejaculation causes a significant increase in the serum PSA concentration in men between 49 and 79 years of age that may persist for up to 48 hours.
[34]
Effect of ejaculation on serum prostate specific antigen level in ... - NIH
The serum PSA levels were increased by more than 4 ng/ml, 1 h after ejaculation, but returned to baseline after 24 h. There was a significant difference between ...
[35]
The effect of finasteride on prostate-specific antigen in men with ...
Finasteride is a specific 5-alpha-reductase inhibitor that has been shown to reduce prostate size and decrease serum levels of prostate specific antigen (PSA).
[36]
5α-Reductase Inhibitors and Time to Diagnosis and Mortality in ...
May 6, 2019 · 5-α Reductase inhibitors also depress serum prostate-specific antigen (PSA) concentrations by approximately 50%. Randomized trials have shown ...
[37]
Ethnic differences in prostate-specific antigen levels in men without ...
Dec 1, 2022 · Black men without prostate cancer have higher PSA levels than White or Hispanic men, which reflects the higher rates of prostate cancer diagnosis in Black men.
[38]
Ethnic differences in prostate-specific antigen levels in men without ...
Dec 1, 2022 · Black men had higher PSA levels than White men, and Hispanic men had similar levels to White men and lower levels than Black men.
[39]
Prostate-Specific Antigen Levels Among Participants Receiving ...
Sep 18, 2025 · In this study, significant intra-individual variability in PSA levels was observed in this large screening cohort, with many elevated values ...
[40]
Assessment of Intra-Individual Variationin Prostate-Specific Antigen ...
The intra-individual variability of free PSA (fPSA) and tPSA was assessed by calculating coefficients of variation (CV) for each individual's PSA measurements ...
[41]
Correlation between the complex PSA/total PSA ratio and the free ...
Some undetectable PSA is complexed with α2-macroglobulin and approximately 10–30% of PSA is not bound to serum proteins and is called free PSA (fPSA).Missing: labile | Show results with:labile
[42]
Biomarkers in prostate cancer surveillance and screening - NIH
Free PSA. PSA circulates in the bloodstream either in a bound or unbound 'free' form. In its bound form PSA is complexed with serine antiproteases such as ...Missing: properties | Show results with:properties
[43]
Identification of Prostate Specific Antigen (PSA) Isoforms in Complex ...
The 2E9 monoclonal antibody, used for detection, is known to recognize PSA as both free and as complexed with α-1-antichymotrypsin [23].Missing: properties | Show results with:properties
[44]
Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA ...
Jul 11, 2014 · PSA has a 17-amino acid leader sequence (preproPSA) that is cleaved co-translationally to generate an inactive precursor protein (proPSA) with ...Missing: biochemical properties
[45]
A new biomarker for prostate cancer: [-2]proPSA
Aug 26, 2020 · [-2]proPSA, a PSA precursor, is a more specific and accurate biomarker indicating prostate biopsy in men at real risk of PCa. by Dr A. Abrate, ...Missing: variants nicked structure
[46]
Novel Biomarkers – Prostate Cancer - Randox Laboratories
Nicked PSA, also referred to as benign PSA, is an inactive form of the PSA protein commonly associated with benign prostate enlargement rather than cancer. It ...
[47]
Free and complexed prostate-specific antigen (PSA) - PubMed
The ease of calibration and the accuracy of free PSA assays in comparison with assays of the PSA-ACT complex suggest that measurements of free to total PSA most ...Missing: differences | Show results with:differences
[48]
Short-term stability of the molecular forms of prostate-specific ...
In the short term (<1 week), fPSA is less stable with storage than tPSA or cPSA in a time- and temperature-dependent fashion.
[49]
Prostate-Specific Antigen Velocity for Early Detection of ... - NIH
Accordingly, the total PSA threshold for prostate biopsy varied slightly between 2.54 and 3.39 ng/ml. ... (PSA) velocity <0.75 ng/ml per year. Total PSA plus age ( ...
[50]
PSA Velocity Does Not Improve Prostate Cancer Detection - NCI
Apr 13, 2011 · Researchers looked at whether a PSA velocity above the 0.35 ng/ml per year threshold—when added to a standard risk model that includes age, PSA ...
[51]
Prostate Specific Antigen Velocity in Men With ... - Journal of Urology
Prostate specific antigen velocity thresholds in the range of 0.4 ng/ml per year should be used to help guide the need for biopsy in men with a total prostate ...Missing: definition | Show results with:definition
[52]
The Role of PSA Velocity in the Early Detection of Prostate Cancer
Feb 6, 2013 · It has been proposed that a PSA rise of 0.75 ng/ml or greater may be concerning for cancer in patients with a PSA between 4 and 10ng/ml, while ...Missing: definition | Show results with:definition
[53]
Prostate Cancer Nomograms: PSA Doubling Time
This tool can be used to calculate the rate of rise of PSA, expressed as the velocity in nanograms/mL/year, or the PSA doubling time, in months or years.
[54]
PSA Velocity and Doubling Time in Diagnosis and Prognosis ... - NIH
PSA doubling time is the number of months it would take for PSA to increase two-fold. The PSA doubling time of our example patient would therefore be 48 months.
[55]
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising ...
Feb 5, 2022 · Individual PSA data were log transformed to eliminate right-skewness in the data distribution. The mathematical modeling of PSA kinetics in the ...
[56]
What Can Skew a PSA Test? 6 Factors To Consider - Ezra
Jan 23, 2025 · A biopsy can elevate PSA levels as few as four hours after the procedure, and the levels may remain elevated for up to four weeks. Avoid PSA ...<|separator|>
[57]
ERSPC - European Randomized Study of Screening for Prostate ...
Jul 28, 2022 · ERSPC latest findings confirm increased mortality benefit from prostate cancer testing · PSA screening cuts deaths by 20%, says world's ...
[58]
PD19-01 VARIATION OF SERUM PROSTATE SPECIFIC ANTIGEN ...
May 1, 2024 · In a large screening trial, we show that PSA levels measured at yearly intervals fluctuate which is why an isolated PSA elevation should be repeated.Missing: studies | Show results with:studies
[59]
[PDF] An examination of the dynamic changes in prostate-specific antigen ...
PSA values are log-transformed to log 2PSA in the logistic regression analysis because the distribution of PSA levels was skewed toward higher levels. Note ...
[60]
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I
Jul 1, 2023 · This guideline addresses PSA-based screening and early detection, considerations for initial and repeat biopsy, and biopsy technique based on a systematic ...
[61]
Early Detection of Prostate Cancer: AUA/SUO Guideline Part... - LWW
According to the new prostate cancer screening guidelines, the use of digital rectal exam (DRE) with PSA is optional (Grade C).<|separator|>
[62]
“A 16-yr Follow-up of the European Randomized study of Screening ...
Feb 26, 2019 · The latest report (2014) showed that PSA screening increased PCa incidence 1.6-fold and the relative reduction in PCa mortality was 21% at 13 yr ...
[63]
Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)
This guideline addresses early detection with an emphasis on PSA-based screening, considerations for initial and repeat biopsy, and biopsy technique.<|separator|>
[64]
ESMO 2025: Men with BRCA1 and BRCA2 gene mutations should ...
Oct 17, 2025 · Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular ...
[65]
Correlation between Prostate Specific Antigen and Prostate Biopsy ...
Dec 9, 2019 · There is a positive correlation between PSA and Gleason score with R-value 0.590 indicating a good degree of correlation. Conclusion: There is a ...<|separator|>
[66]
Importance of prostate-specific antigen (PSA) as a predictive factor ...
The RP-based Gleason score appears to be a stronger predictor of PSA-based failure after RP than the biopsy-based Gleason score (7). The discrepancy between the ...
[67]
An updated prostate cancer staging nomogram (Partin tables) based ...
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 ... Results: The median PSA was 4.9 ng/mL, 63% had Gleason 6 disease, ...
[68]
An updated prostate cancer staging nomogram (Partin tables) based ...
Jul 26, 2012 · The 'Partin tables' use commonly available preoperative data – serum PSA level, clinical stage and biopsy Gleason score – to predict pathological stage at ...
[69]
Postoperative prostate-specific antigen nadir improves accuracy for ...
We have previously shown that postoperative PSA nadir is highly associated with disease recurrence and overall survival, being potentially useful in risk ...
[70]
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline
BCR is defined as a detectable or rising PSA level ≥0.2 ng/mL on 2 separate determinations after undergoing RP with curative intent for prostate cancer (nadir ...
[71]
Guiding Treatment for Patients With Prostate Cancer With ...
Mar 12, 2025 · Biochemical recurrence is commonly defined as 2 consecutive PSA values of ≥ 0.2 ng/mL. This setting is like a puzzle.
[72]
Ten-year survival rates by PSA nadir in patients with metastatic ...
Aug 22, 2025 · We present updated final 10-year survival outcomes from the CHAARTED trial in overall and prespecified prognostic groups and PSA nadir (<0.2 ng/ ...Missing: resistant thresholds
[73]
Patterns of Cancer Progression of Metastatic Hormone-sensitive ...
For current studies, PCWG3 defines PSA progression as a 25% increase over nadir with a minimum absolute level of 1 ng/ml. Herein, we report an analysis of the ...
[74]
Prostate-Specific Antigen Density: A Measurement to Differentiate ...
Jul 24, 2020 · PSAD is a simple, inexpensive, and good tool that can be used to differentiate BPH from prostate cancer in the gray zone of serum PSA between 4 and 10 ng/mL.
[75]
Utilizing Prostate Specific Antigen Density to Enhance Diagnostic ...
Mean PSA density for BPH patients: 0.0844 ng/ml/cm3. Mean PSA density for prostate cancer patients: 0.172 ng/ml/cm3.
[76]
Extremely Elevated Prostate-Specific Antigen in Acute Prostatitis - NIH
Aug 18, 2023 · Significantly elevated PSA levels > 1,000 ng/mL can be observed in non-cancerous prostatic conditions such as acute prostatitis among others. So ...
[77]
Does normalizing PSA after successful treatment of chronic ... - NIH
Treatment of chronic prostatitis with elevated PSA by antibiotics and anti-inflammatory agents can decrease the elevated PSA to the normal levels.
[78]
Prostate specific antigen measurements after minimally invasive ...
Nov 27, 2000 · At 1 y follow-up, mean PSA decreased 32% for laser patients, 46% for the TURP cohort and 8% for TVP group. The largest mean decrease in PSA ...<|separator|>
[79]
Prostate specific antigen levels following transurethral resection of ...
PSA decreases drastically in patients who undergo TURP. These low levels stabilize within 60 days after surgery. The f/t PSA ratio did not change.
[80]
Altered prostate specific antigen reference range after transurethral ...
After a TURP with a benign histopathologic specimer) PSA levels decrease steadily to values below 2 ng/ml. In case these patients demonstrate a rising PSA ...
[81]
Comparison in prostate cancer diagnosis with PSA 4–10 ng/mL
... PSA levels ranging from 4 to 10 ng/mL, usually referred to as the “gray zone”. Less than 25% of men with a prostate-specific antigen (PSA) level in the gray ...
[82]
Predicting prostate cancer in men with PSA levels of 4–10 ng/mL
Mar 24, 2023 · However, PSA level of 4–10 ng/mL is termed as the gray zone, as there is no clear consensus on the indication for performing biopsy in these ...
[83]
Prostate cancer statistics, 2025 - Kratzer - CA
Sep 2, 2025 · Prostate cancer mortality rates increased until 1993 and have since declined by more than 50% through 2023, in part because of earlier detection ...
[84]
Cancer Stat Facts: Prostate Cancer - SEER
The death rate was 19.2 per 100,000 men per year. These rates are age-adjusted and based on 2018–2022 cases and 2019–2023 deaths. Lifetime Risk of Developing ...Missing: decline PSA
[85]
Prostate-Specific Antigen (PSA) Testing - Landmark Studies - SEER
Prostate cancer mortality also began to decline in the early 1990s, and the decline has continued. Randomized controlled trials have not yet confirmed the ...
[86]
Screening and Prostate-Cancer Mortality in a Randomized ...
PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
[87]
A 16-yr Follow-up of the European Randomized study of Screening ...
Conclusions: Findings corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up ...
[88]
A Detailed Evaluation of the Effect of Prostate-specific Antigen ...
Prostate-specific antigen–based prostate cancer screening reduces metastasis and mortality. Longer follow-up shows fewer invitations and diagnoses needed to ...
[89]
Stage shift in PSA detected prostate cancers - NIH
This paper aims to investigate whether the stage shift (where more cancers are detected at an earlier stage) in PSA-detected cancers differs by Gleason score.
[90]
Prostate Cancer Screening (PDQ®) - NCI
Apr 8, 2025 · PSA testing has increased the detection rate of early-stage cancers, some of which may be curable by local-modality therapies, and others ...
[91]
U.S. County-level Study Shows Life-Saving Impact of PSA Screening
A new study of U.S. counties found that higher rates of prostate-specific antigen (PSA) screening are linked to lower incidences of advanced or metastatic ...
[92]
Prostate cancer screening in African American men: a review of the ...
Given the higher burden of prostate cancer among African American men, the risks and benefits of PSA-based screening may differ for African American men.
[93]
New Guidelines: Start PSA Screening Earlier in Black Men - Medscape
Jan 29, 2024 · Starting PSA screening in Black men earlier would reduce prostate cancer deaths by about 30%.<|separator|>
[94]
Prostate Cancer Foundation Highlights Evidence-Based Prostate ...
Jun 18, 2024 · Since Black men are at high risk for prostate cancer, the benefits of screening generally outweigh the risks. Prostate-specific antigen (PSA) ...
[95]
Overdiagnosis due to prostate-specific antigen screening - PubMed
Conclusions: Among men with prostate cancer that would be detected only at autopsy, these rates correspond to overdiagnosis rates of, at most, 15% in whites ...Missing: studies | Show results with:studies
[96]
Overdiagnosis and Overtreatment of Prostate Cancer - ScienceDirect
Epidemiological, clinical, and autopsy studies have been used to examine PCa overdiagnosis, with estimates ranging widely from 1.7% to 67%.
[97]
Recommendation: Prostate Cancer: Screening - uspstf
May 8, 2018 · Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms ...
[98]
Prostate-Specific Antigen–Based Screening for Prostate Cancer ...
May 8, 2018 · In the ERSPC trial, 27 men needed to be diagnosed (and potentially treated) to prevent 1 prostate cancer death, underscoring the potential for ...<|separator|>
[99]
[PDF] Prostate Cancer Screening
PSA has a false positive rate of about 70% and a false negative rate of about 20%. Although screening for prostate cancer with PSA can reduce mortality from ...
[100]
PSA & Prostate Cancer - Alaska Urology
However, because an elevated PSA between 4-10 ng/ml is only predictive of cancer in approximately 30% of patients, a more precise way of looking at PSA is ...
[101]
[PDF] Reducing overtreatment of prostate cancer by radical prostatectomy ...
50%–75% of patients with low-risk cancer received radical ... Active surveillance compared with initial treatment for men with low-risk prostate cancer: a ...
[102]
Management of functional outcomes after radical prostatectomy in ...
Oct 10, 2023 · The incidence of ED after RP ranges from about 25% to 75%, while UI has been reported in 4% to 31% of patients after 1 year of follow-up, ...
[103]
Urinary incontinence and erectile dysfunction in patients ... - PubMed
Jul 15, 2020 · Before treatment, 54% of patients reported ED. Among the 46% remaining patients, 87% of patients treated with radical prostatectomy reported ED ...
[104]
Long-term outcomes of active surveillance for prostate cancer - NIH
The risk of progression from Grade Group 1 to Grade Group 2 or 3 at 5, 10, and 15 years was 24% (95% CI 22%–26%), 36% (95% CI 33%–39%), and 41% (95% CI 35%–46%) ...
[105]
Extended follow-up for prostate cancer incidence and mortality ...
After almost 17 years of median follow-up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm.
[106]
A new study claims prostate cancer screenings significantly reduce ...
Sep 4, 2017 · If the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent ...
[107]
Prostate-Specific Antigen Levels Among Participants Receiving ...
Sep 18, 2025 · Data were analyzed from February 10, 2023, to May 23, 2025. Main Outcomes and Measures The primary outcome was the proportion of PSA ...Missing: studies | Show results with:studies
[108]
Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening
The original MISCAN model fitted to ERSPC Rotterdam data predicted a mean lead time of 7.9 years and an overdiagnosis estimate of 66%; in the model that was ...Context And Caveats · Figure 3 · Discussion
[109]
[PDF] p30 Tests for the Forensic - Abacus Diagnostics
Semenogelin concentrations range from 4–68 mg Sg/mL and are generally higher than PSA concentrations, which typically range from 0.2–5.5 mg PSA/mL in seminal.<|separator|>
[110]
Identity of Prostate Specific Antigen and the Semen Protein P30 ...
We conclude that PSA and the semen protein p30 are identical and can be easily purified by a rapid continuous technique.
[111]
Detection of prostate specific antigen by ELISA - PubMed
A method for the detection of prostate specific antigen (PSA or P30) by enzyme linked immunosorbent assay (ELISA) has been developed.
[112]
Detection of Prostate Spesific Antigen P30 for Forensic Purpose by ...
Apr 1, 1998 · Detection of Prostate Spesific Antigen P30 for Forensic Purpose by Using the Ouchterlony Technique Double Diffusion in Agar. Bull Leg Med ...
[113]
Evaluation of prostate-specific antigen (PSA) membrane test assays ...
PSA membrane test assays offer the same sensitivity as ELISA-based tests and provide a rapid approach for the forensic identification of seminal fluid.
[114]
Semen test will make rape detection easier - UPI Archives
Feb 6, 1985 · The development of a test that can detect semen in women up to two days after sex may help police convict more rapists, a team of California ...
[115]
Comparison between prostate specific antigen and acid ...
The PSA test was better than the AP test for semen detection in the vaginal swabs, and the combined results (AP + PSA) were better than the individual tests.
[116]
[PDF] SERATEC® PSA CRIME SCENE BOX
The advantages of a PSA determination are: • The detection of PSA is possible in cases where no spermatozoa can be found (for example vasectomized men). • Very ...
[117]
Good Performance of Rapid Prostate-Specific Antigen Test for ...
This study evaluated the performance of a rapid PSA test compared with a quantitative assay to identify semen in vaginal swab specimens.Missing: applications | Show results with:applications
[118]
Combination of prostate-specific antigen detection and micro ...
Namely, the presence of PSA and nucleated cells in male urine could lead a forensic examiner to an incorrect body fluid conclusion.
[119]
Laboratory Orientation and Testing of Body Fluids and Tissues for ...
Jun 28, 2023 · However, the currently accepted method of choice for identification of semen in all circumstances is detection of p30 using the ABAcard® test ...
[120]
Diagnostic value of prostate health index in patients with no index ...
Feb 17, 2025 · PHI showed superior specificity in detecting clinically significant PCa compared with PSA alone. This advancement has reduced overdiagnosis ...
[121]
https://pmc.ncbi.nlm.nih.gov/articles/PMC12546309/
[122]
Evaluation of Phi Clinical Performance for the Detection of Prostate ...
Their study showed that phi had a greater specificity for distinguishing clinically-significant PCa via biopsy compared with total PSA or %fPSA [19]. A meta- ...
[123]
Personalised Prostate Cancer Diagnosis: Evaluating Biomarker ...
Apr 15, 2025 · In both studies, the 4Kscore test showed good calibration and discrimination (AUC >0.80), while significantly reducing the number of biopsies.
[124]
Implementation of 4Kscore as a Secondary Test Before Prostate ...
Sep 2, 2025 · 4Kscore is a widely used secondary test that has been shown to reduce biopsy rates by approximately two-thirds in routine clinical practice. We ...
[125]
A urine-based Exosomal gene expression test stratifies risk of high ...
The ExoDx Prostate (IntelliScore) EPI test is a validated, non-invasive urine exosome gene expression assay that performs equally well for men at initial biopsy ...
[126]
The ExoDx™ Prostate Test & mpMRI – A Complementary Approach
Using the ExoDx Prostate Test either before or after mpMRI are possible approaches for layered risk assessment and more informed decision-making.
[127]
Advancements in artificial intelligence for prostate cancer
Feb 21, 2025 · Empirical evidence shows that AI models exhibit higher sensitivity and specificity in detecting clinically significant PCa, outperforming ...
[128]
New biomarkers and multiplex tests for diagnosis of aggressive ...
Feb 25, 2025 · While PSA, 4K score, PCA3 and other urinary markers, ExoDX, SelectMDX, Confirm MDx or MiPS tests are used to identify potential prostate cancer carriers.
[129]
The discovery of prostate-specific antigen - PubMed
In 1971, Hara characterized a unique protein in the semen fluid, gamma-seminoprotein. ... In 1979, Wang purified a tissue-specific antigen from the prostate (' ...
[130]
The discovery of prostate‐specific antigen - Rao - BJU International
Aug 30, 2007 · In 1971, Hara characterized a unique protein in the semen fluid, γ-seminoprotein. Li and Beling, in 1973, isolated a protein, E1, from human ...
[131]
Purification of a human prostate specific antigen. 1979 - PubMed
Purification of a human prostate specific antigen. 1979. ... M C Wang, L A Valenzuela, G P Murphy, T M Chu. PMID: 11905925; DOI: 10.1016 ...Missing: et al serine protease
[132]
PURIFICATION OF A HUMAN PROSTATE SPECIFIC ANTIGEN
The prostate antigen was purified to homogeneity from prostatic tissues and showed a single protein band on analytical polyacrylamide gel electrophoresis and ...
[133]
Prostate Specific Antigen (PSA): The Historical Perspective
Dec 1, 2020 · Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Investigative Urology 17: 159-163; 1979. Wang MC, ...
[134]
Prostatic specific antigen. From its early days until becoming a ...
Some years later, Hara, a Japanese forensic investigator, found 'gamma ... He finally received the patent for the discovery of "human purified prostate antigen" ...
[135]
[PDF] Acces~~~g'8BECKMAN - accessdata.fda.gov
In the late 1990s, an international standard for total PSA (the WHO 1st International. Reference Preparation 96/670) became available. An increasing number ...<|separator|>
[136]
Prostate-specific antigen as a serum marker for adenocarcinoma of ...
We conclude that PSA is more sensitive than PAP in the detection of prostatic cancer and will probably be more useful in monitoring responses ...Missing: Stenman | Show results with:Stenman
[137]
F.D.A. Approves Prostate Blood Test - The New York Times
Aug 31, 1994 · Many doctors have been using the test as a diagnostic aid even though it was approved in 1986 only as a means to monitor the progress of ...
[138]
Screening for prostate cancer: Controversy? What controversy? - PMC
When the U.S. Food and Drug Administration (fda) approved the psa test in 1994 for screening, the approval was not based on rigorous study of the specificity ...
[139]
Standardization of PSA measures: a reappraisal and an experience ...
The Hybritech® PSA Test was the first FDA-approved assay (1986) for prostate cancer monitoring and the first. FDA-approved assay (1994) for prostate cancer ...
[140]
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Mar 18, 2009 · After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
[141]
mortality results after 13 years of follow-up - PubMed - NIH
Jan 18, 2012 · Conclusions: After 13 years of follow-up, there was no evidence of a mortality benefit for organized annual screening in the PLCO trial compared ...
[142]
Press Releases Archives - ERSPC
May 1, 2023 · PSA screening cuts deaths by 20%, says world's largest prostate cancer study. Stockholm, Sweden (18 March 2009). Screening for prostate cancer ...
[143]
Archived: Prostate Cancer: Screening - uspstf
May 15, 2012 · The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)-based screening for prostate cancer. D ...
[144]
EAU Guidelines on Prostate Cancer - Uroweb
The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa.Prostate Cancer · Treatment · Diagnostic Evaluation · Follow-up